Ikena Oncology (NASDAQ:IKNA – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Ikena Oncology Stock Performance
Shares of IKNA stock opened at $1.29 on Tuesday. The stock’s fifty day moving average is $1.50 and its 200-day moving average is $1.63. The stock has a market capitalization of $62.25 million, a PE ratio of -1.05 and a beta of 0.48. Ikena Oncology has a 52 week low of $1.22 and a 52 week high of $1.94.
Analyst Ratings Changes
Several research firms recently issued reports on IKNA. Wedbush reiterated a “neutral” rating and issued a $2.00 price target on shares of Ikena Oncology in a report on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Ikena Oncology in a report on Monday, November 11th.
Ikena Oncology Company Profile
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Read More
- Five stocks we like better than Ikena Oncology
- What Are Earnings Reports?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
